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Abstract: Innovation in medicine is a dynamic, complex, and
continuous process that cannot be isolated to a single moment in time.
Anniversaries offer opportunities to commemorate crucial discoveries of
modern medicine, such as penicillin (1928), polio vaccination (inacti-
vated, 1955; oral, 1961), the surface antigen of the hepatitis B virus
(1967), monoclonal antibodies (1975), and the ﬁrst HIV antiretroviral
drugs (zidovudine, 1987). The advent of antiretroviral drugs has had
a profound effect on the progress of the epidemiology of HIV infection,
transforming a terminal, irreversible disease that caused a global health
crisis into a treatable but chronic disease. This result has been driven by
the success of antiretroviral drug combinations that include nucleoside
reverse transcriptase inhibitors such as lamivudine. Lamivudine, an L-
enantiomeric analog of cytosine, potently affects HIV replication by
inhibiting viral reverse transcriptase enzymes at concentrations without
toxicity against human polymerases. Although lamivudine was
approved more than 2 decades ago, it remains a key component of
ﬁrst-line therapy for HIV because of its virological efﬁcacy and ability
to be partnered with other antiretroviral agents in traditional and novel
combination therapies. The prominence of lamivudine in HIV therapy is
highlighted by its incorporation in recent innovative treatment strategies,
such as single-tablet regimens that address challenges associated with
regimen complexity and treatment adherence and 2-drug regimens being
developed to mitigate cumulative drug exposure and toxicities. This
review summarizes how the pharmacologic and virologic properties of
lamivudine have solidiﬁed its role in contemporary HIV therapy and
continue to support its use in emerging therapies.
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INTRODUCTION
Lamivudine (29-deoxy-39-thiacytidine, 3TC) is a ﬁrst-
generation nucleoside reverse transcriptase inhibitor (NRTI) that
was approved for the treatment of HIV-1 infection in 1995 and
hepatitis B virus (HBV) infection in 1998.1,2 Lamivudine has
been evaluated in more than 50 clinical studies registered on
ClinicalTrials.gov involving .25,000 patients. Since 2002, the
World Health Organization (WHO) has been recommending
treatment regimens for HIV infection, and both 3TC or
emtricitabine (FTC) are preferred components of nearly all
ﬁxed-dose combinations.3 Moreover, in the updated 2016 WHO
guidelines, 3TC continues to be recommended as part of ﬁxed-
dose combinations as ﬁrst- and second-line antiretroviral therapy
(ART) for adults, adolescents, children, and infants.3 In addition,
WHO recommends that patients coinfected with HIV and HBV
use a ﬁrst-line ART combination containing tenofovir disoproxil
fumarate (TDF) plus 3TC or FTC. The WHO guidelines are
consistent with those recommended by the International Anti-
viral Society,4 European AIDS Clinical Society,5 and the US
Department of Health and Human Services.6–8 HIV treatment
has evolved to include single-tablet regimens containing potent
3- or 4-drug combinations, and 3TC has remained a well-
established component in many combination strategies as HIV
treatment continues to evolve.
BIOCHEMISTRY OF 3TC
Investigators ﬁrst reported on the promise of the racemic
mixture of BCH-189 to treat HIV-19 and HBV.10 On separation
of the enantiomers in this mixture, the plus and minus forms of
BCH-189 were found to have activities against the replication of
HIV-1 and HIV-2.11,12 However, the minus (non-natural)
enantiomer was unexpectedly more potent than the plus (natural)
enantiomer, was associated with markedly less cytotoxicity in
human lymphocyte cultures, and was therefore developed as an
antiretroviral therapeutic.11–13 After approval from the US Food
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and Drug Administration (FDA), this levo-enantiomer was
given the name “lamivudine.”
Lamivudine is a nucleoside analog of 29-deoxycytosine9
that exerts its antiviral effects by acting as a DNA chain
terminator (Fig. 1). The active anabolite of 3TC, lamivudine
59-triphosphate, is formed from phosphorylation by intracellu-
lar kinases and competes with naturally occurring cytidine
triphosphate for incorporation into DNA.14,15 Lamivudine is
a potent inhibitor of the reverse transcriptase (RT) enzymes of
HIV-1, with in vitro IC50 in different cell lines with different
HIV-1 strains ranging from 0.002 to 1.14 mM9,11–13 and IC50
against HBV of 0.1 mM10 with limited cell toxicity at
concentrations .1000-fold than those effective against HIV.
The unnatural nucleoside structure of 3TC, an L-(2)-enantio-
mer, is not recognized as a substrate by human polymerases
(all natural nucleosides have a D conﬁguration) at biologically
relevant concentrations. The unique chemical structure of 3TC,
which is characterized by excellent antiviral activity with little
toxicity, strongly contributes to its clinical success.
Early characterization of 3TC revealed that resistance to
the drug develops rapidly in vitro.16 Compared with other
NRTIs, resistance to 3TC or FTC occurs via mutations (see
Table, Supplemental Digital Content 1, http://links.lww.com/
QAI/B131, which shows major mutations associated with
resistance to NRTIs).17 Mutations of codon 184 result in
substitution of isoleucine or valine in place of the wild-type
methionine via a missense mutation (M184I or M184V).16
Amino acid 184 is located in the highly conserved tyrosine–
methionine–aspartate–aspartate (YMDD) motif of HIV-1 RT
(necessary for proper catalytic function of the enzyme) and
confers high-level (.100-fold) resistance to 3TC.16,18 How-
ever, the mutation was also found to increase susceptibility to
zidovudine (ZDV)19 and, subsequently, to stavudine (d4T)20
and tenofovir.21 In addition, by affecting the catalytic
function of RT, M184V lowers processivity and enhances
ﬁdelity of HIV RT, resulting in low viral ﬁtness. Puriﬁed
M184V variant proteins have exhibited 2- to 6-fold reduced
mutation frequency compared with wild-type RT,22,23 per-
haps contributing to the reduced rate of drug resistance. The
combination of these effects results in residual antiviral
activity, even in the presence of 3TC monotherapy, in patients
who harbor the M184V/I substitution.24 In a 48-week
prospective study of 58 evaluable patients with virologic
failure on ART containing 3TC and with evidence of
treatment-emergent M184V substitution, immunological or
clinical failure occurred in 69% of patients who discontinued
ART at baseline and 41% of patients who continued ART
with 3TC monotherapy (P = 0.064).24 In addition, in a study
of 1895 patients randomized to receive 3TC, 3TC and
loviride, or placebo in combination with their current regimen
of either ZDV, ZDV and didanosine (ddI), or zalcitabine
(ddC), 3TC reduced the risk of HIV disease
progression by 57% compared with placebo (hazard ratio,
0.42; P , 0.0001).25 Because of the possible beneﬁts of
M184V, guidelines recommend considering continuation of
3TC or FTC in particular situations even if M184V has been
documented.3,26 Clinical data in 132 treatment-experienced,
virally suppressed patients infected with HIV containing
multiple mutations, including M184V, demonstrated that
a boosted protease inhibitor [ritonavir-boosted darunavir
(DRV/r) or ritonavir-boosted lopinavir (LPV/r)] plus 3TC
was superior to boosted protease inhibitor monotherapy, with
only 4 patients [3%; 95% conﬁdence interval (CI) 0.8 to 7.6]
experiencing viral failure after 48 weeks of treatment.27 These
data support the hypothesis that selection of M184V by 3TC
results in residual antiviral activity that can be effective in
controlling viral replication in combination with other
antiviral agents.
PHARMACOLOGY
Lamivudine is rapidly absorbed after oral administra-
tion, with maximum serum concentrations reached between
FIGURE 1. (A) Structures of lamivudine and other NRTIs used
in contemporary HIV therapy. (B) Mechanism of action of
NRTIs. aTenofovir (TFV) is the active moiety of TDF and teno-
fovir alafenamide fumarate (TAF).
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0.5 and 1.5 hours after dosing and a dominant elimination
half-life of approximately 5–7 hours (Table 1).14 The absolute
bioavailability of 3TC is 82% in adults and 68% in children.
Systemic exposure is not affected when 3TC is administered
with food and is consistent across sex and race. The in vitro
intracellular half-life of lamivudine 59-triphosphate is 10.5–
15.5 hours in HIV-infected cell lines and 17–19 hours in
HBV-infected cell lines, which supports a minimum dosing
interval of 12 hours. Approximately 5.2% of 3TC is
metabolized and excreted as a minor product, with the
majority remaining unchanged and undergoing active organic
cationic secretion through the kidneys.28
Considering 3TC’s low metabolic clearance, minimal
binding to plasma protein, and no observed effects on hepatic
metabolism, it is expected that 3TC would have few clinically
relevant pharmacological interactions with concomitantly
administered drugs.14 Of note, ZDV, ddI, cotrimoxazole, and
interferon-a-2b have all been shown to result in minor
pharmacokinetic changes that do not require a dose adjust-
ment.14 In a 2012 study, an unexpected interaction was
observed between oral solutions of abacavir (ABC) and oral
solutions of 3TC,29 which led to a 2017 study to determine
whether sorbitol, an excipient of other antiviral liquid for-
mulations, alters 3TC pharmacokinetics (PK) by altering
osmolarity in the intestine, thus reducing the absorption.30
Maximal concentrations of plasma 3TC were shown to be
reduced in a dose-dependent manner as much as 55% when
coadministered with sorbitol 13.4 g; plasma 3TC exposure was
reduced by 36%–44% in the presence of sorbitol 13.4 g.30
Decreases in plasma exposure corresponded to increased
apparent oral clearance by 57% with sorbitol 13.4 g. Therefore,
it is likely that avoiding coadministration of 3TC and sorbitol-
containing medicines will be recommended, requiring a switch
to tablet regimens.
Because the potential viral replication in reservoir sites,
such as the genital tract and the central nervous system, is an
important challenge to preventing transmission and the future
possibility of cure, it is important to understand the drug’s PK
in these sites.31 On the basis of PK modeling, concen-
trations of 3TC and the active triphosphate analog 3TC-TP
with the ﬁrst dose were greater than the targeted IC50 in
seminal mononuclear cells and peripheral blood mono-
nuclear cells (PBMCs), partially because of the long half-
life in seminal mononuclear cells (159 hours) compared
with PBMCs (5 hours). Another PK model estimated that
the ratio of 3TC exposure in the cervicovaginal ﬂuid to that
in the blood plasma was between 4.6 and 9.9 (at ﬁrst dose
and multiple doses) depending on the strength of the dose,
suggesting a high level of 3TC disposition into the female
genital tract.32 By contrast, study results on 3TC penetra-
tion into the central nervous system have been inconsistent.
In a preclinical study in primary human fetal astrocytes and
astrocyte cell lines, 3TC was less potent in astrocytes
compared with PBMCs, resulting in an estimated 90%
inhibitory concentration for 3TC in astrocytes being 12-
fold greater than the maximum 3TC concentration that
could occur in the cerebrospinal ﬂuid (CSF).33 However, in
a PK study of children aged 8–18 years infected with HIV,
the median (interquartile range) CSF concentration of 3TC
was 97 (51–144) ng/mL, which is much higher than the
reported IC50 of 0.5–3.4 ng/mL, suggesting that 3TC
demonstrates antiviral potency in the CSF in children.34
EARLY DRUG DEVELOPMENT
When 3TC was in clinical development, HIV infection
was treated with ﬁrst-generation NRTI monotherapy using
ZDV, ddI, ddC, or d4T. The limited clinical success of this
approach motivated the investigation of 2-drug combinations.
Clinical trials of ZDV in combination with ddC or ddI were
the ﬁrst to demonstrate that concurrent or alternating
administration of 2 NRTIs was superior to administration of
ZDV alone.35–37
Lamivudine was evaluated in clinical studies alone and
in combination with ZDV. The NUCA 3001 and NUCA 3002
studies in North America and the NUCB 3001 and NUCB
TABLE 1. Virological, Biochemical, and Pharmacological Characteristics of NRTIs Used in Contemporary HIV Therapy
3TC ABC FTC ZDV TDF* TAF*
HIV-1 reverse transcriptase in MT-4 cells†, mean
(SD, n), mM104–106
2.1 (0.6, 7) 4.0 (1.6, 21) 0.5 (NA, 2–3) 0.040 (0.005, 51) 4.2 (0.8, 2) 0.005 (0.002, 2)
Intracellular half-life, h75,107 10.5–15.5 3.3 .20 3–4 .60 NA108‡
Plasma or serum T1/2, h75,107,109 5–7 1–2 7–10 0.8–1.9 17 0.4
Reverse transcriptase Ki§k, mean (SE), nM110–112 233 (28) 10 (1)¶ 430 (60) 4.4 (2) 980 (NA)# NA
Relative mtDNA content after 25 days of treatment,
mean % vs untreated control cells** (SD)61,113
137 (7) 134 (27) 110 (15) 118 (24) 101 (20) 107 (16)
3TC, lamivudine; ABC, abacavir; EC50, drug concentration needed to inhibit 50% of viral spread; FTC, emtricitabine; IC50, half-maximal inhibitory concentration; Ki, apparent
inhibitor dissociation constant; mtDNA, mitochondrial DNA; n, number of determinations; NA, not available; SD, standard deviation; SE, standard error of the mean; TAF, tenofovir
alafenamide fumarate; TDF, tenofovir disoproxil fumarate; ZDV, zidovudine.
*Active moiety is tenofovir diphosphate.
†IC50 for 3TC, ABC, FTC, and ZDV; EC50 for TDF and TAF.
‡Could not be estimated.
§Inhibition constants for the triphosphate analogs of 3TC, ABC, FTC, and ZDV.
kValues were generated using a homopolymeric RNA/DNA template for 3TC; DNA template for TDF, FTC, and ZDV; and RNA template for ABC.
¶In the form of carbovir, the active metabolite of ABC.
#Average standard error for Ki values for TDF and its analogs was 16%.
**Changes were observed after 25 days of treatment in HepG2 cells for 3TC, ABC, FTC, and ZDV; changes were observed after 10 days of treatment in MT-2 cells for TDF and TAF.
J Acquir Immune Defic Syndr  Volume 78, Number 2, June 1, 2018 Lamivudine for HIV Treatment
Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc. www.jaids.com | 127
3002 studies in Europe conducted between 1993 and 1994
were the ﬁrst randomized controlled trials to evaluate the
efﬁcacy of 3TC.38–41 The trials compared the combination of
3TC and ZDV with ZDV monotherapy38–40 and ZDV in
combination with ddC,42 with change from baseline in CD4+
cell counts as the primary end point; reduction in plasma viral
load was evaluated as an exploratory end point. The results of
these trials at 52 weeks showed increased CD4+ cell counts in
the combination treatment groups, whereas CD4+ counts were
slightly decreased or similar to baseline in the ZDV or 3TC
monotherapy treatment groups, respectively. More impor-
tantly, viral load was signiﬁcantly reduced at 52 weeks in the
combination group compared with smaller decreases in either
monotherapy group.39 The trials that studied 2 different doses
of 3TC found no signiﬁcant differences between the 150-mg
twice-daily and 300-mg twice-daily doses in viral load
reduction and CD4+ cell counts.39,40 A subsequent trial
showed similar efﬁcacy in patients receiving 3TC 300 mg
once-daily versus 3TC 150 mg twice-daily when combined
with ZDV and efavirenz (EFV).43
RESISTANCE
The efﬁcacy of 3TC monotherapy was limited by the
early development of a mutation causing the M184I sub-
stitution in RT (followed by emergence of M184V), detected
within the ﬁrst month of 3TC monotherapy in both treatment-
naive and treatment-experienced patients.28,44 Although HIV-
1 RNA reduction of 1.3 logs occurred in the ﬁrst 2–4 weeks
of 3TC monotherapy, selection of the M184V mutant virus
resulted in a subsequent rebound in viral load, leading to an
overall viral load reduction of 0.5 logs at 48 weeks.28 An
in vitro analysis of heterogeneous mixtures of M184V and
wild-type HIV showed that the relative concentration of
M184V had to be at least 20% to result in a .1-fold increase
in 3TC resistance and more than 50% to result in a fold
change greater than 3TC’s clinical cutoff of 3.5; these results
were consistent with the reported assay validation data (Fig.
2).45 Interestingly, after selection of M184V, some in vitro
activity of 3TC was retained when it was combined with other
agents, even in the presence of full resistance to 3TC.46 In
vitro studies showed that the M184V variant preferentially
incorporates deoxycytidine triphosphate instead of lamivu-
dine 59-triphosphate 20- to 100-fold more frequently than
wild-type virus.15 This mechanism of resistance contrasts
with the mechanism of ZDV resistance. Reverse transcriptase
carrying ZDV resistance mutations still incorporates ZDV,
but chain termination is relieved by excision of the terminal
nucleotide analog; ZDV resistance mutations accelerate the
rate of excision reaction.47 The M184V mutation sensitizes
HIV-1 ZDV and reverses the effect of ZDV resistance
mutations by reducing the rate of ZDV excision.47 Therefore,
the observed sustained response to 3TC/ZDV combination
therapy is explained in part by the sensitization to ZDV by the
M184V mutation.48 The synergy between 3TC and ZDV
played a crucial role in early suppressive therapy against HIV
and heralded the beginning of the combination ART era with
3TC/ZDV, the ﬁrst antiretroviral ﬁxed-dose combination.
Mechanistic studies have also demonstrated that
a reduction in HIV replicative capacity by an estimated
10% leads to a reduction in ﬁtness associated with the M184V
variant.48 The presence of the M184V substitution further
reduces the viral ﬁtness of HIV viruses carrying other drug
resistance mutations known to affect viral ﬁtness (eg, K65R
in RT and R263K in integrase).49,50 Slower replication of
mutant viruses may further reduce viral ﬁtness in CD4+
lymphocytes, which possess low concentrations of deoxynu-
cleoside triphosphates.46,51 Interestingly, 3TC has shown
FIGURE 2. Effect of differing relative concentrations of either M184V or K65R mutations when combined with wild-type HIV. 3TC,
lamivudine. Reproduced from Underwood MR, Ross LL, Irlbeck DM, et al. Sensitivity of phenotypic susceptibility analyses for
nonthymidine nucleoside analogs conferred by K65R or M184V in mixtures with wild-type HIV-1. J Infect Dis. 2009;199(1):84–88,
by permission of the Infectious Diseases Society of America.
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residual in vitro activity in monocyte-derived macrophages
(MDMs) in the presence of the M184V substitution that was
potentially driven by speciﬁc conditions of these HIV target
cells (Fig. 3).52 In MDMs, resistance to 3TC via the M184V
pathway occurs more slowly than in other cells. Thus,
selection for M184V by 3TC is weaker in MDMs compared
with other cell types, leading to the possibility of residual
activity of 3TC in cells displaying less frequent mitosis
compared with cultured tumor cells.52 The M184I reverse
transcriptase isolated from the serum of a single patient
infected with HIV-1 exhibited decreased DNA polymeriza-
tion in the presence of low concentrations of deoxynucleotide
triphosphate (dNTP) in vitro compared with wild-type HIV
reverse transcriptase, which was explained by the low binding
afﬁnity of M184I to dNTPs.53 Macrophages have lower
dNTP concentrations compared with other cell types (4 and
20 times less than in resting and activated T cells, respec-
tively).54 Interestingly, the HIV M184I virus was unable to
transduce macrophages but was able to transduce cell types
with higher dNTP concentrations. These biochemical and
preclinical data suggest that preservation of M184V by
continued selection pressure of 3TC may be clinically
beneﬁcial by preventing the overgrowth of wild-type virus,46
especially in cells with low dNTP concentrations such
as macrophages.
It has been postulated that the lower replication activity
of M184V variants could result in a reduction in HIV
transmissibility. It has been noted that although M184V is
commonly acquired during treatment with NRTIs, it is rarely
detected in treatment-naive patients, suggesting that M184V
variants are rarely transmitted.55 According to 1 study that
used population genetic sequencing, 67.5% of patients with
virologic failure on ﬁrst-line treatment harbored M184V
variants compared with only 7% of those who were treatment
naive.55 However, when a polymerase chain reaction–based
method was used to detect minority subpopulations of HIV
variants in the sample, 23.4% of treatment-naive patients
harbored M184V variants, whereas the method of detection
did not substantially affect the reported frequency of other
variants. The differences in the results of the 2 methods reﬂect
the rate at which M184V is overcome by other genotypes
within the viral population. In 3 individual samples from
treatment-naive patients with M184V originally present, the
percentage of M184V decreased over time and was no longer
detectable between 40 and 61 weeks after the infection. The
combination of these results suggests that the replication
FIGURE 3. In vitro inhibition of wild-type, two-TAM, andM184V HIV-1 by 3TC in P4 cells and MDMs (A) 4 hours pretreatment and (B)
16 hours pretreatment. Data represent mean values of quadruplicate wells. Independent experiments (n = 11) were performed with
MDMs from different donors. 3TC, lamivudine; MDM, monocyte-derived macrophage; RLU, relative light unit; TAM, thymidine analog
mutation. Republished with permission of American Society for Microbiology—Journals, from Perez-Bercoff D, Wurtzer S, Compain S,
Benech H, Clavel F. Human immunodeficiency virus type 1: resistance to nucleoside analogues and replicative capacity in primary
human macrophages. J Virol. 2007;81(9):4540–4550; permission conveyed through Copyright Clearance Center, Inc.
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defect of M184V does not substantially affect HIV trans-
mission, but the reduced ﬁtness causes the elimination of
M184V in the absence of selection by 3TC or FTC.
Studies of mono- and dual-NRTI regimens suggest
residual clinical beneﬁt of 3TC despite the presence of
M184V mutants.39,56,57 For example, in NUCA 3001, plasma
HIV-1 RNA levels remained .0.5 log10 below baseline in
participants who received 3TC monotherapy despite emer-
gence of the M184V substitution and high-level phenotypic
resistance.56 Moreover, in a small pilot study, withdrawal of
3TC in viremic patients with multidrug-resistant HIV and the
M184V substitution led to a 0.5 log10 increase in viral load at
6 weeks, suggesting a persistent antiviral effect of 3TC
despite the presence of the M184V substitution.58 These and
other clinical observations suggest a beneﬁt of continuing
3TC even in the presence of M184V mutants; however,
determining the clinical relevance of this beneﬁt may require
further study.57,59
SAFETY
Since the approval of NRTIs, postmarketing reports of
adverse reactions have been collected,1 and numerous
toxicities were associated with prolonged use of ﬁrst-
generation NRTIs. A widely accepted hypothesis is that
many of these toxicities result from inhibition of mitochon-
drial DNA (mtDNA) polymerase g.
The potential for mitochondrial toxicity of ﬁrst-
generation NRTIs was generally high, with ddI, d4T, and
ddC most strongly associated with toxicities and ZDV
showing a weaker, but still relevant, association.60,61 With
the emergence of combination ART, 3TC was combined with
other NRTIs in early trials, which made it difﬁcult to identify
the drug that caused any given AE. However, preliminary
safety data from the NUC trials revealed that the addition of
3TC did not result in toxicities beyond those associated with
other components of the combination regimen.39,40 Similar
safety results have been demonstrated in more recent clinical
studies.62 These data suggested that the safety proﬁle of 3TC
may be different from that of other NRTIs. Active 3TC
metabolites are not concentrated in the mitochondria, which
may explain why a subsequent in vitro analysis revealed that
3TC had no effect on cell growth, lactate production,
intracellular lipids, mtDNA, and mtDNA-encoded respiratory
chain subunit II of cytochrome c oxidase after a long-term
treatment.61 Another explanation for this lack of mitochon-
drial toxicity is the weaker inhibition constant of the minus
enantiomer of 3TC for mitochondrial DNA polymerase g.63
Similarly, the minus form’s weaker inhibition of DNA
polymerase a translates to less toxicity caused by off-target
inhibition of nuclear DNA synthesis. In a case control
retrospective analysis, there was an 87% risk reduction (odds
ratio, 0.13; 95% CI: 0.06 to 0.26; P , 0.001) in experiencing
hyperlactataemea/lactic acidosis while taking 3TC compared
with taking other NRTIs (including TDF, d4T, ABC, ddI, and
ZDV), suggesting that the risk of developing lactic acidosis
is minimal for patients treated with 3TC.64 Thus, from both
in vitro and clinical studies, there is little evidence of
a negative effect of 3TC on mitochondrial biology.
Although morphologic changes (lipoatrophy and lip-
ohypertrophy) and insulin resistance are considered to be
clinical features of HIV, some ART regimens are believed to
FIGURE 4. Proportion of patients in individual studies who achieved viral load ,50 copies per milliliter after 48 or 52 weeks on
therapy. Treatment was lamivudine in combination with antiretroviral drugs listed below the x-axis. ABC, abacavir; d4T, stavu-
dine; DTG, dolutegravir; FPV/r, fosamprenavir/ritonavir; IDV, indinavir; LPV/r, lopinavir/ritonavir; NFV, nelfinavir; ZDV, zidovu-
dine.
Quercia et al J Acquir Immune Defic Syndr  Volume 78, Number 2, June 1, 2018
130 | www.jaids.com Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc.
contribute to these metabolic ﬁndings. In contrast with results
using thymidine-containing NRTIs, clinical studies of 3TC
plus ABC combination therapy demonstrated small increases
in lipohypertrophy and no increased risk of lipoatrophy.65,66
Similarly, the risk of developing insulin resistance is reduced
with 3TC plus ABC combination therapy compared with
a thymidine-containing combination.66 These data suggested
that 3TC may have a favorable toxicity proﬁle compared with
other NRTIs.
PEDIATRICS
Children infected with HIV at birth are an example of
a population that needs nuanced care. Lamivudine is
approved for children aged 3 months to 16 years when the
dosage is scaled to body weight,1 and it is included as an
NRTI backbone agent in every WHO-recommended ﬁrst-line
regimen for treatment of children, adolescents, and pregnant
or breastfeeding women at any CD4+ cell count, regardless of
the clinical stage.3 The inclusion of 3TC in recommended
regimens is attributable to its well-established record of
efﬁcacy and safety in children living with HIV.67–69
Lamivudine has been evaluated as a component of
combination therapy for its capacity to decrease the risk of
mother-to-child HIV transmission and infant mortality.70
Antiretroviral therapy prevented HIV transmission to an
estimated 670,000 children in low- and middle-income
countries from 2009 to 2012.71 The Kesho Bora
study demonstrated that infants of mothers treated
with 3TC-containing ART during pregnancy and
breastfeeding had a decreased risk of HIV transmission
(43% reduction, P = 0.029), mortality, and HIV transmission
or death (36% reduction, P = 0.017) at 12 months compared
with mothers treated with ART that did not include 3TC.72
An even greater decrease in HIV transmission risk (48%
reduction, P = 0.02) was seen in infants whose mothers were
treated with 3TC and intended to breastfeed compared with
non–3TC-treated mothers who intended to breastfeed.
COMPARISON OF 3TC AND FTC
Like 3TC, FTC is a dideoxynucleoside analog of
cytosine used to treat HIV infection, and the 2 drugs share
similar characteristics and safety proﬁles as shown in head-to-
head studies.73,74 Emtricitabine is more potent than 3TC
in vitro and has a longer intracellular half-life (Table 1).75 By
contrast, 3TC achieves higher intracellular levels of the active
triphosphate analog than does FTC.76 The terminal half-life of
FTC 200 mg once-daily is 7.4 hours,77 which is similar to that
of 3TC 300 mg administered once-daily (7.9 hours).78 Similar
to 3TC, single-agent FTC has been shown to select for
M184V in vitro approximately 2 weeks after initiation.79 In
a pooled analysis of trials in which the treatment-naive
patients received EFV plus 2 NRTIs that included
either 3TC or FTC, the frequency of patients with observed
M184V/I variants was 1.0% in patients treated with FTC and
3.2% in patients treated with 3TC (P = 0.009).80 However,
conclusions from this analysis were limited by the nature of
the cross-trial comparison, including different NRTI partners.
Emtricitabine and 3TC are usually considered clinically
equivalent. A phase II dose-escalation study demonstrated
that a daily 200-mg dose of FTC had superior virologic
efﬁcacy compared with 150 mg of 3TC administered twice-
daily.81 However, in the context of combination ART, 3TC-
and FTC-containing regimens have comparable efﬁcacy.82 A
recent review evaluated clinical trials that studied 3TC and
FTC as part of combination therapy for treatment-naive or
treatment-experienced adults infected with HIV from 2002 to
2013.82 Twelve clinical trials provided 15 different random-
ized comparisons, providing data on 2251 patients receiving
3TC and 2662 patients receiving FTC. In the 12 trials,
treatment outcomes were not signiﬁcantly different. In 3 trials
that compared 3TC and FTC directly, the relative risk of
treatment success was nonsigniﬁcant (RR, 1.03; 95% CI: 0.96
to 1.10; P = 0.3). For all 12 trials, the pooled relative risk of
treatment success was not signiﬁcantly different (RR, 1.00;
95% CI: 0.97 to 1.02). Similarly, there was no difference in
the pooled relative risk of treatment failure (RR, 1.08; 95%
CI: 0.94 to 1.22). A retrospective, exploratory analysis of
pooled data from 3 phase III studies that evaluated the safety
and efﬁcacy of dolutegravir-based regimens provided further
support for the clinical similarity of the 2 agents.83 A Kaplan–
Meier estimate of time to efﬁcacy-related discontinuation or
failure (ERDF), stratiﬁed by NRTI backbone and HIV-1 RNA
level at baseline (#100,000 or .100,000 copies per mL),
supported a conclusion that risk of ERDF was not signiﬁ-
cantly different for participants treated with ABC/3TC versus
TDF/FTC (regardless of third agent) overall (HR 0.90, 95%
CI: 0.58 to 1.38, P = 0.63) or in patients with baseline HIV-1
RNA .100,000 copies per milliliter (HR 0.95, 95% CI: 0.55
to 1.65, P = 0.86).
By contrast, a study of 4740 treatment-naive patients
infected with HIV-1 without baseline resistance from the
ATHENA cohort in the Netherlands who were treated with
3TC or FTC plus an NNRTI (EFV or nevirapine) and
tenofovir found that virologic failure occurred more often in
patients treated with 3TC than in patients treated with FTC
[odds ratio (OR; 95% CI) with EFV/tenofovir, 1.78 (1.11 to
2.84), P = 0.016; with nevirapine/tenofovir, 2.09 (1.25–3.52),
P = 0.005].84 However, in another study from the ATHENA
cohort of 1582 treatment-naive patients with HIV who
initiated treatment with 3TC or FTC plus a boosted PI and
TDF, no signiﬁcant differences in rates of virologic failure
were observed in patients taking 3TC compared with patients
taking FTC.85 Collectively, these ﬁndings support the current
US treatment guidelines to consider FTC and 3TC as
interchangeable for initial therapy,6 with the possibility that
further head-to-head prospective studies may be warranted to
evaluate whether the interchangeable nature of FTC and 3TC
should be context speciﬁc based on ART regimen.
3TC IN NOVEL 2-DRUG REGIMENS
A new clinical strategy has been proposed to increase
patient adherence and reduce toxicities associated with
chronic ART to improve patient outcomes by switching from
3- or 4-drug combinations to 2-drug regimens. This approach
is recommended by treatment guidelines in speciﬁc
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situations.5,6 Clinical trials with treatment-experienced pa-
tients have analyzed the safety and efﬁcacy of switching to
a 2-drug regimen, including several combinations that include
3TC (see Table, Supplemental Digital Content 2, http://links.
lww.com/QAI/B131, which details clinical studies involving
2-drug regimens containing 3TC and an NRTI, non-NRTI,
integrase inhibitor, or boosted protease inhibitor). In the
SALT trial, ATV/r plus 3TC was noninferior to ATV/r plus 2
NRTIs and had signiﬁcantly fewer treatment discontinua-
tions.86 The similarly designed ATLAS study showed that
ATV/r plus 3TC exhibited superior efﬁcacy to ATV/r plus 2
NRTIs at 48 weeks (P = 0.027).87 In the OLE trial, 3TC
paired with LPV/r showed similar efﬁcacy and tolerability
compared with LPV/r plus 2 NRTIs in virologically sup-
pressed participants.88 Highly ART-experienced adults (n =
27) switched to DTG plus 3TC in the DOLULAM study
maintained viral suppression (,50 copies per milliliter) for
96 weeks with no serious or clinical adverse events.89
Interestingly, ultradeep sequencing analysis determined that
the M184I/V substitution was observed in 63% (n = 17) of
patients enrolled in DOLULAM, yet no virologic failure was
observed over the course of the study.90
The 2-drug treatment strategy with 3TC has demon-
strated success with treatment-naive patients as well. Lam-
ivudine plus LPV/r was noninferior to the 3-drug regimen of
LPV/r plus 2 NRTIs at 48 weeks in the GARDEL trial.91
Because DRV/r is better tolerated than LPV/r,92 the ANDES
trial compared DRV/r plus 3TC with DRV/r plus 3TC/TDF,
and the interim analysis indicated that the study achieved
a secondary end point, noninferiority of DRV/r plus 3TC in
patients achieving HIV-1 RNA ,400 copies per milliliter at
24 weeks.93 The primary end point, viral load ,50 copies per
milliliter at 48 weeks, will be reported after the next phase of
the study is complete. There were 5 serious adverse events
(DRV/r + 3TC, 3; DRV/r + 3TC/TDF, 2), none of which were
considered drug related, and 5 discontinuations from the
study (DRV/r + 3TC, 4; DRV/r + 3TC/TDF, 1). The
PADDLE pilot study evaluated DTG and 3TC as a 2-drug
regimen in treatment-naive patients with HIV-1 infection and
showed that 90% of patients were virologically suppressed at
48 weeks,94 and 100% of patients (n = 18) who were included
in the extension phase maintained virologic suppression at 96
weeks.95 To extend the ﬁndings of PADDLE, 3TC was paired
with DTG in patients with HIV-1 RNA ,500,000 copies per
milliliter in the phase II 52-week ACTG A5353 pilot study.96
After 24 weeks, DTG plus 3TC demonstrated potent virologic
efﬁcacy, with 90% of participants (n = 108) meeting the
primary end point for virologic success (HIV-1 RNA ,50
copies per milliliter); 3 participants experienced protocol-
deﬁned virologic failure, including 1 participant with muta-
tions resulting in R263K and M184V detected at week 14.
Pharmacokinetic data showed DTG concentrations below the
limit of detection at $1 visit. Two participants experienced
grade 3 adverse events considered to be treatment related but
did not discontinue the study. Last, in the open-label ASPIRE
trial with 89 patients with virologic suppression on 3-drug
ART, 93.2% of patients who switched to DTG plus 3TC
maintained virologic suppression compared with 91.1% of
patients who remained on their initial regimen (P = 0.71) at
the 24-week primary analysis, demonstrating noninferiority of
DTG plus 3TC.97 These proof-of-concept studies provide the
rationale for 2 phase III trials, GEMINI-1 (clinicaltrials.gov
identiﬁer, NCT02831673) and GEMINI-2 (clinicaltrials.gov
identiﬁer, NCT02831764), which compare DTG/3TC with
DTG plus TDF/FTC in treatment-naive patients. The out-
comes of these studies will provide strong clinical trial
evidence for evaluating this innovative strategy.
CONCLUSIONS
Despite its 25-year history as a component of anti-
retroviral treatment regimens, 3TC continues to be studied,
and new aspects of its fascinating virology and mechanism of
action continue to be uncovered. Over the past 2 decades,
treatment options associated with 3TC have improved as the
combinations have become more potent, safer, and more
convenient.74,91,98–103 (Fig. 4) As new drugs and drug classes
have been approved, regimens that contain 3TC continue to
be widely used in ﬁrst-line therapy. In developing countries,
3TC is critical to HIV care because of its excellent efﬁcacy
and safety proﬁle and the availability of low-cost generic
versions. Indeed, 3TC is recommended in nearly all ﬁrst-line
and a majority of second-line combination regimens for both
adults and children. In addition, 3TC has a well-established
PK proﬁle with few drug–drug interactions, which is
important not only for the convenience of combining 3TC
with other drugs in single-tablet regimens but also because of
the prevalence of multiple comedications in certain popula-
tions such as the elderly or hepatitis-coinfected patients.
Among all drugs ﬁrst approved more than 20 years ago for
HIV treatment, only 3TC continues to be recommended in the
most recent worldwide guidelines. With few drug–drug
interactions and low cost, 3TC continues to emerge and play
a role in new treatment strategies worldwide in combination
with a new generation of antiretroviral drugs and remains an
attractive component for inclusion in future
drug combinations.
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